Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection.

MLA

Tsimafeyeu, Ilya, et al. “Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Chronic Hepatitis C Virus Infection.” Cancer Immunology, Immunotherapy : CII, vol. 69, no. 6, June 2020, pp. 983–88. EBSCOhost, https://doi.org/10.1007/s00262-020-02521-y.

APA

Tsimafeyeu, I., Gafanov, R., Protsenko, S., Semenova, A., Oganesyan, A., Nurgaliyev, N., Krasny, S., Bondarenko, A., Safina, S., & Zakurdaeva, K. (2020). Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection. Cancer Immunology, Immunotherapy : CII, 69(6), 983–988. https://doi.org/10.1007/s00262-020-02521-y

Chicago

Tsimafeyeu, Ilya, Rustem Gafanov, Svetlana Protsenko, Anna Semenova, Ani Oganesyan, Nurzhan Nurgaliyev, Sergei Krasny, Anastasia Bondarenko, Sufia Safina, and Kristina Zakurdaeva. 2020. “Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Chronic Hepatitis C Virus Infection.” Cancer Immunology, Immunotherapy : CII 69 (6): 983–88. doi:10.1007/s00262-020-02521-y.